💰️️ Startup Radar • FUNDING

DeepTech / Biotechnology 🇮🇹 Bologna, Italy

🚀 Cellply raised €7.15M round Latest funding round
🎯 Pitch: Developing analytical tools and the VivaCyte® platform for deep characterization of cancer immunotherapies and cell-based biotherapeutics at single-cell resolution.
🏗️ Growth Plans: Accelerate international commercial expansion of VivaCyte® and develop next-generation automated functional testing for ATMP quality control.
💼 Investors: ENEA Tech e Biomedical • CDP Venture Capital • Recomec • LIFTT • Schia Ventures
🔍 B2B Potential: International market expansion • ATMP quality control automation • Cell potency assessment precision

👥 Team

Alessia Zanelli - President and CEO
Massimo Bocchi - Founder
Roberto Guerrieri - Founder
Miro Venturi - Board Member